Novo Nordisk launches ESPEROCT® in the U.S. for the treatment of people with hemophilia A

The following is an excerpt from a press release from Novo Nordisk. Read the press release in its entirety here.

Novo Nordisk announced ESPEROCT^® [antihemophilic factor (recombinant), glycopegylated-exei] is now available in the U.S. for the treatment of adults and children with hemophilia A. ESPEROCT^® is a recombinant extended half-life factor VIII replacement therapy used to prevent or reduce the number of bleeding episodes, to treat and control bleeding, and to manage bleeding during surgery in people with hemophilia A.
“At Novo Nordisk, we have a longstanding commitment to the hemophilia community, beginning with the development of our first recombinant factor therapy more than 30 years ago,” said Pia D’ Urbano, Corporate Vice President, Biopharmaceuticals, Novo Nordisk Inc. “We recognize that people with rare bleeding disorders need multiple therapy options and are proud to now make ESPEROCT^® available as a new treatment option for those living with hemophilia A, the most common form of the chronic bleeding disorder.”
Hemophilia A is a chronic, inherited bleeding disorder, which affects nearly 20,000 people in the U.S. Hemophilia A is the most common form of hemophilia.^ People with hemophilia A have deficient factor VIII activity that interferes with blood clotting and results in prolonged or spontaneous bleeding.² Bleeding episodes can be debilitating, as they often cause pain and can lead to chronic swelling, reduced mobility, and long-term joint damage. Approximately 60 percent of those living with hemophilia A have the severe form of the disorder.
ESPEROCT^® replaces the clotting Factor VIII that people with hemophilia A are missing. Compared to standard half-life treatments, which require multiple intravenous injections, ESPEROCT^® helps people with hemophilia A maintain high Factor VIII levels longer, helping reduce frequency of bleeding with less frequent dosing.^ 
Read the press release in its entirety here.